SCHOLAR ROCK HOLDING CORPORATION Lessee, Operating Lease, Liability, Undiscounted Excess Amount
SCHOLAR ROCK HOLDING CORPORATION (SRRK) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $1.04 million as of 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-03-03
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1.04M.
- 2024-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $2.64M.
- 2023-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $749.00K.
- 2022-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1.95M.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2025-12-31 | $1.04M 10-K · filed 2026-03-03 |
| 2024-12-31 | $2.64M 10-K · filed 2025-02-27 |
| 2023-12-31 | $749.00K 10-K · filed 2024-03-19 |
| 2022-12-31 | $1.95M 10-K · filed 2023-03-07 |
| 2021-12-31 | $3.73M 10-K · filed 2022-03-07 |
| 2020-12-31 | $6.03M 10-K · filed 2021-03-09 |
| 2020-09-30 | $6.64M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $544.00K 10-Q · filed 2020-08-07 |
| 2020-03-31 | $624.00K 10-Q · filed 2020-05-07 |
| 2019-12-31 | $709.00K 10-K · filed 2020-03-12 |
| 2019-09-30 | $797.00K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $857.00K 10-Q · filed 2019-08-14 |
| 2019-03-31 | $952.00K 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |